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ABSTRACT
Deregulated expression of E2F1 not only promotes
S-phase entry but also induces apoptosis. Although
it has been well documented that E2F1 is able to
induce p53-dependent apoptosis via raising ARF
activity, the mechanism by which E2F induces
p53-independent apoptosis remains unclear. Here
we report that E2F1 can directly bind to and activate
the promoter of Smac/DIABLO, a mitochondrial pro-
apoptotic gene, through the E2F1-binding sites BS2
( 542  535bp)andBS3( 200  193bp).BS2and
BS3 appear to be utilized in combination rather
than singly by E2F1 in activation of Smac/DIABLO.
Activation of BS2 and BS3 are E2F1-specific, since
neither E2F2 nor E2F3 is able to activate BS2 or
BS3. Using the H1299 ER-E2F1 cell line where
E2F1 activity can be conditionally induced, E2F1
has been shown to upregulate the Smac/DIABLO
expression at both mRNA and protein levels
upon 4-hydroxytamoxifen treatment, resulting in
an enhanced mitochondria-mediated apoptosis.
Reversely, reducing the Smac/DIABLO expression
by RNA interference significantly diminishes apo-
ptosis induced by E2F1. These results may suggest
a novel mechanism by which E2F1 promotes p53-
independent apoptosis through directly regulating
its downstream mitochondrial apoptosis-inducing
factors, such as Smac/DIABLO.
INTRODUCTION
The E2F transcription factor family is the key regulators of
cell proliferation, which were ﬁrst described for their necessity
by adenovirus E1A protein for transactivating the adenovirus
E2 promoter (1). E2Fs control the cell cycle by regulating
the expression of a number of genes, whose products are
required for the S-phase entry and cell cycle progression
(2). The E2F proteins themselves can be negatively regulated
by the retinoblastoma tumor suppressor RB, which exhibits
the growth suppression activity by interacting with E2Fs to
shield their transactivation domain (3). Of the eight E2F pro-
teins identiﬁed thus far, E2F1 is the best-characterized mem-
ber. It promotes cell cycle by regulating critical regulator
genes involved in the DNA replication and G1/S transition (4).
In addition, numerous studies have suggested that ectopic
expression of E2F1 induces apoptosis by different mecha-
nisms (5–13) and consistently, E2F1-deﬁcient mice exhibit a
defect in thymocyte apoptosis and an increasing susceptibility
to the development of tumors (14,15). The E2F1-p14ARF-p53
cascade is the most important p53-dependent apoptotic
pathway for E2F1. During this signaling, E2F1 upregulates
p14ARF, which in turn stabilizes p53 and promotes p53-
induced apoptosis by alleviating the proteosome degradation
of p53 by Mdm2 (16,17). Recently, it has been shown that
ARF directly binds toDP1(aDNA-bindingpartnerofE2Fs)to
inhibit its transcriptional activity, which implies a novel nega-
tive feedback loop between ARF and E2F1 (18–20). In addi-
tion to the p53-dependent pathway, many genes involved in
p53-independent apoptotic regulation have also been demon-
strated as E2F1 targets (4), such as p73 (21,22), Apaf1 (23,24),
caspase-3, -7, -8, -9 genes (25,26), BH3-only genes noxa,
puma, bim (27) and akt (28).
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doi:10.1093/nar/gkl150Smac (the second mitochondria-derived activator of cas-
pase), also known as DIABLO (direct IAP-binding protein
with low pI), is normally compartmentalized and stored in
mitochondria after protein translation (29–32). Upon receiving
apoptotic stimuli, Smac/DIABLO is released into cytosol,
where it binds to IAPs and allows the activation of caspases
by eradicating IAP’s caspase-binding capability or enhancing
the proteosome-mediated degradation ofIAPs(33,34). Altered
expression of Smac/DIABLO has been reported in some
cancer cells, e.g. downregulation of Smac/DIABLO has
been observed in renal cell carcinoma (35) and lung cancers
(36), and Smac/DIABLO upregulation was detected in Folic
acid-induced acute renal failure (37). However, the detailed
molecular mechanism underlying regulation of Smac/
DIABLO remains uncharacterized.
In this report, we present the ﬁrst evidence that E2F1
can bind to the Smac/DIABLO promoter and transactivate
its expression. Two putative E2F1-binding elements BS2
and BS3 were located respectively within the regions
 542/ 535 and  200/ 193 relative to the transcriptional
initiation site (+1) of Smac/Diablo gene were characterized.
Transactivation of Smac/DIABLO promoter by E2F1 can
achieve its maximal induction only when BS2 and BS3 are
jointly utilized. Repression of Smac/DIABLO by RNA inter-
ference (RNAi) technique attenuates the E2F1-induced apop-
tosis, indicating Smac/DIABLO is positioned downstream of
this E2F1-mediated apoptotic signaling pathway. Similarly,
enhanced accumulation of nuclear E2F1 induced by
4-hydroxytamoxifen (4-OHT) upregulates Smac/DIABLO,
resulting into an augmented mitochondria-mediated apoptosis.
These data suggest that Smac/DIABLO may act as a target
gene for E2F1 and contribute to a novel E2F1-induced
apoptosis via p53-independent pathway.
MATERIALS AND METHODS
Reagents and antibodies
The following antibodies were used in this study: Smac/
DIABLO rabbit polyclonal antibody (Calbiochem, LA Jolla,
CA); E2F1 rabbit polyclonal antibody H-137 and C-20 (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA); HA mouse mono-
clonal antibody (Cell Signaling Technology Inc., Danvers,
MA); Noxa mouse monoclonal antibody (Imgenex Corp.,
San Diego, CA); Cytochrome C mouse monoclonal antibody
(R&D Systems Inc., Minneapolis, USA); b-actin goat poly-
clonal antibody (Santa Cruz Biotechnology); Rhodamine-
conjugated anti-rabbit IgG secondary antibody (Jackson
ImmunoResearch Laboratories, Inc). The majority of reagents
used for this study including 4-OHT and Hoechst 33342 were
purchased from Sigma-Aldrich, Inc. Restriction enzymes were
ordered from New England Biolabs (Beverly, MA).
Plasmids construction and the isolation of
the Smac/Diablo promoter
The UCSC Genome Browser Database, the Genomatix Suite
of sequence analysis tools MatInspector (professional version
6.2.2) and PromoterInspector Release 1.0 were used for ana-
lyzing the Smac/Diablo promoter. Primer pairs ﬂanking single
or combinations of putative E2F-binding sites used for PCR
were synthesized and listed below. Genomic DNA isolated
from human lung carcinoma H1299 cells by Wizard Genomic
DNA Puriﬁcation Kit (Promega Corporation, Madison, WI)
was used as a template for PCR to obtain a 1.5 kb ( 1000  
+500) genomic fragment. Various promoter deletion frag-
ments were obtained with primer pairs indicated below.
Brieﬂy, Pa and Pii are used for PCR ampliﬁcation of P1234,
Pa and Pi for P123, Pb and Pii for P234, Pb and Pi for P23, Pc and
Pii for P34, Pc and Pi for P3, Pb and Piii for P2, Pd and Pii for
P0. The promoter fragments were subcloned into the XhoI/
HindIII sites of pGL3-Basic plasmid (Promega Corporation).
Pa, 50-CCG CTC GAG CAC AGA AGA GCA GGT TTG
GGC CTG-30; Pb, 50-CCG CTC GAG CCG TCC GCC CCT
CTG GGA CGG CGC-30; Pc, 50-CCG CTC GAG AGC TCC
GCG CCG GAC CCG CCT-30; Pd, 50-CCG CTC GAG GTA
CCG CTG CGG CCG CGT-30; Pi, 50-CGC AAG CTT AGC
AGT CGG GAT TGG GCA GGC-30; Pii, 50-CGC AAG CTT
CTG CAG CGC TAG GTA GAG AGC-30; Piii, 50-CGC AAG
CTT TGA GTC GGG CGC CGT GAC-30.
The E2F genes are kindly gifted from Dr Stefan Gaubatz
and Dr Doron Ginsberg and subcloned into pcDNA3 or
pEGFP-C1 vector by standard techniques. The plasmids
pGL3-Apaf1 ( 396/+208) (23) and pBabeHAERE2F1 (38)
are kind gifts from Dr Kristian Helin.
Cell culture and transfection
Human H1299 nonsmall lung carcinoma cells were cultured
in RPMI-1640 medium containing 10% (v/v) fetal bovine
serum (FBS) with 2 mM L-glutamine adjusted to contain
1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM HEPES
and 1.0 mM sodium pyruvate, and a culture of HeLa cervical
carcinoma cells was grown in DMEM supplemented with 10%
(v/v) FBS, 1· nonessential amino acid, 100 mg/ml penicillin,
1· MEM sodium pyruvate, 100 mg/ml streptomycin. Culture
medium was purchased from Invitrogen Corporation (Gibco,
Grand Island, NY). Cells were maintained at 37 Ci na
humidiﬁed 5% CO2-containing atmosphere. Tranfection of
cells with various mammalian expression constructs by
Lipofectamine  2000 (Invitrogen, Carsbad, CA) was per-
formed according to the methods provided by manufacturer’s
speciﬁcation. Transfection of Smac/DIABLO siRNA oligo
(sc-36505; Santa Cruz) and irrelevant control siRNA oligo
(sc-37007; Santa Cruz) was carried out by Oligofectamine 
reagent (Invitrogen).
ER-E2F1-expressing H1299 cell lines were derived from
H1299 cells as described previously (23). Brieﬂy, H1299 cells
were infected by retroviruses produced in Phoenix cells trans-
fected with pBabeHAER-E2F1. Infected H1299 cells were
selected by puromycin (2 mg/ml) for 10 days. Expression of
ER-E2F1 proteins in the selected cells was conﬁrmed by west-
ern blotting with E2F1-speciﬁc antibodies C-20 (Santa Cruz)
and HA-speciﬁc antibodies (Cell Signaling Technology, Inc.),
respectively. Immunoﬂuorescence with speciﬁc anti-E2F1
antibodies (H-137; Santa Cruz) in absence or presence of
OHT (1 mM) was carried out to examine the translocation
of the ER-E2F1 from the cytoplasm into the nucleus and
hence their activation.
Semiquantitative RT–PCR
For semiquantitative RT–PCR, H1299 cells stably express-
ing ER-E2F1 were ﬁrst incubated in RPMI-1640 medium
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length of time with 1 mM 4-OHT. Total RNA was isolated
from the 4-OHT treated H1299 cells by SV Total RNA Isola-
tion System (Promega Corporation) and 0.1 mg RNA of each
sample was used as template. RT–PCR was performed by
TaKaRa One-step RNA PCR Kit (AMV) (TaKaRa Bio Inc.,
Japan) using the following speciﬁc primer pairs: Smac/
DIABLO, 50-ATG GCG GCT CTG AAG AGT TGG CTG
and 50-TCA ATC CTC AAC GCA GGT AGG TCC-30;
b-actin, 50-GAC CTG ACT GAC TAC CTC ATG AAG
AT-30 and 50-GTC ACA CTT CAT GAT GGA GTT AAG
G- 3 0; Cyclin A, 50-ATG AGA CCC TGC ATT TGG CTG-30
and 50-TTG AGG TAG GTC TGG TGA AGG-30.
Chromatin immunoprecipitation assay (ChIP)
ChIP assays were performed as described previously (27,39).
Brieﬂy, HeLa cells (5 · l0
6 cells) were ﬁxed with formalde-
hyde and then sonicated to obtain soluble chromatin. After
dilution, the chromatin solutions were incubated with and
without anti-E2F1 antibody (sc-193X; Santa Cruz) and placed
on a rotating platform at 4 C overnight. Immunocomplexes
were recovered with preblocked protein A–Sepharose beads.
After extensive washing, the bound DNA fragments were
eluted. The resulting DNAs were subjected to PCRs using
primer sets denoted in the Figure 1a and the detailed sequences
are listed as follows: P1u, 50-GAG CAG GTT TGG GCC TGT
GCC TTC-30 and P1d, 50-AAC TGC CCT CGT TCT TCG
GCT CTG-30 for BS1; P2u, 50-GCT GTT GGG GAG GTC
GGC ACT GTG-30 and P2d, 50-GCC CCG ATG AGC ACC
GTG TAG CTG-30 for BS2; P3u, 50-TTC CCT TCA AGC
CCT GGC CCG AAC-30 and P3d, 50-ACG CCC CCA CCC
AAG GAA GCA GTC-30 for BS3; P4u, 50-TCC TTG GGT
GGG GGC GTG GCT ATG-30 and P4d, 50-CGT CGG TCC
CTC CCT CTG GTC CTG-30 for BS4. PCR products were
separated by gel electrophoresis on a 2% agarose gel and
visualized.
Assessment of apoptosis by Annexin V staining
Annexin V-FITC Apoptosis Detection kit (PharMingen, San
Diego, CA) was used in this assay. Cells were harvested and
resuspended in 100 ml binding buffer (0.01 M HEPES/NaOH,
pH7.4; 0.14 mM NaCl, 2.5 mM CaCl2) at the concentration of
1 · 10
6 cells/ml. After incubation with 5 ml of Annexin
V-FITC and 10 ml of PI (50 mg/ml) at room temperature
for 15 min in the dark, cells were analyzed by ﬂow cytometry
FACS Calibar using the Cell Quest software system (Becton
Dickinson, San Diego, USA) (40). The percentages of apop-
tosis of the cells were calculated by data from FACS analysis
and the result (% Apoptosis) is presented in the bar graph
relative to the apoptosis in cells without treatment with
small interfering RNA of Smac, which is depicted as 100%.
(b)
(c)
(a)
Figure 1. Putative E2F1-binding sites are located in Smac/Diablo genomic
locus.(a)HumangenomicsequenceofSmac/Diablogenefrom 1000to+500
upstream is shown. The first exon is underlined and the transcription initiation
site (+1) is indicated. The boxed are the putative E2F1-binding sites and the
shadedregionisthepredictedSmac/Diablopromoter.Thearrowrepresentsthe
primersusedinChIPassay,itslengthdemarkedthenumbersofbasesforprimer
and its orientation is 50–30. P1u, primer 1 upstream, P1d, primer1 downstream,
same as the rest of the primers. (b) Schematic representation of various Smac/
Diablo promoter deletion constructs. Putative E2F-binding sites are indicated.
The Promoter constructs (P) harboring various E2F-binding sites were cloned
into pGL3-Basic reporter vector (Promega). Primers used to subclone all these
deletionconstructsareindicated.ThesubscriptnumbersinletterPrepresentthe
number of E2F1-binding sites included in each construct. (c) Alignment of the
putative E2F-binding sites with the consensus sequence. In the consensus
sequence, S can be C or G. All the E2F1-binding sites (BS) are in 50 to 30,
the plus indicates the reading is in the downstream direction relative to Smac/
Diablo ORF, and (minus) indicates the use of complimentary stand.
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ER-E2F1-expressing H1299 cells were grown on coverslips,
and treated with 1 mM 4-OHT for 24 h. Cells were ﬁxed in 4%
paraformaldehyde for 10 min, permeabilized with 0.1% Triton
X-100 in phosphate-buffered saline (PBS) for 5 min, and
blocked with 1% BSA in PBS for 30 min. Afterward, cells
were incubated with E2F1 rabbit polyclonal antibody (H-137;
Santa Cruz) at 4 C overnight. Rhodamine-conjugated anti-
rabbit IgG secondary antibody was used to detect E2F1.
Hoechst 33342 (5 mg/ml) was used to stain cell nucleus for
5 min. The cells were visualized under ﬂuorescence micro-
scope using standard red and blue ﬁlter sets. Images were
(a) (1) (2)
(b) (1) (2)
(c)
(d)
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scope (magniﬁcation 400·) controlled by image processing
software named in situ imaging system (ISIS). Western
blotting was performed according to the protocol described
by Song et al. (40).
Dual-luciferase reporter assays
H1299 cells were seeded into 12-well (5 · 10
5 cells per well)
plates and cultured for 20 h in RPMI-1640 medium plus 10%
FBS before transfection. H1299 cells were transiently cotrans-
fected with appropriate Smac/Diablo luciferase reporter
plasmids (200 ng) and either empty vector or E2F1 trans-
activator vector (50   200 ng) using Lipofectamine  2000
(Invitrogen).Ineachtransfection,cellswere alsocotransfected
with Renilla luciferase reporter plasmid. Fireﬂy and Renilla
luciferase activity were assayed using Dual-Luciferase
Reporter Assay System according to manufacturer’s instruc-
tions (Promega). Fold-activation values were measured
relative to the levels of luciferase activity in cells transfected
with empty vectors and normalized by Renilla luciferase
activities.
RESULTS
Identification of E2F1-binding sites at
Smac/DIABLO gene locus
To explore whether potential E2F1-binding elements residing
in the genomic locus of Smac/Diablo promoter region exist,
we employed computer softwares PromoterInspector Release
1.0 and MatInspector (professional version 6.2.2), of which
the former was used to inspect potential promoter regions
and the latter for possible transcription factor-binding sites.
Four putative E2F1-binding sites (BS) were found within the
region from 1000 to +500 bp upstream of transcription initia-
tion site of Smac/Diablo gene (Figure 1a). Among the four
putative E2F1-binding sites, only BS3 is accurately located
within the predicted Smac/Diablo promoter region (high-
lighted with gray shading,  435    12 bp), whereas BS2
is next to BS3 and BS1 is further upstream. It is interesting to
note that BS4 located downstream of BS3 is found to be within
the ﬁrst exon of Smac/Diablo gene (Figure 1b). This is not
unusual, E2F1-binding site for Cyclin A, myc and the hox3D
genes, for example, are also reported to be located within its
exon (25,41,42). The E2F-binding consensus sequence is
50-TTTSSCGC-30 or 50-GCGSSAAA-30, where S can be C
or G. Except for BS1, which contains a T instead of C at
its 30 end, the remaining three putative E2F1-binding sites
exhibit high homology to consensus E2F1-binding sequence
(Figure 1c).
E2F1 activates Smac/DIABLO promoter
To verify whether these potential E2F1-binding sites truly
associate with E2F1 and how effective do they work in
transactivating Smac/DIABLO expression. A series of
Smac/DIABLO promoter deletion mutants were constructed
as shown in Figure 1b. A p53-null cell line H1299 was chosen
for transfection in order to exclude the unanticipated inﬂuence
directly or indirectly from p53. An equal amount of reporter
plasmids containing different E2F1-binding sites indicated
in Figure 2a was individually cotransfected into H1299
cells with the same amount of either empty pEGFP-C1 or
pEGFP-E2F1 transactivator plasmid. Equal concentrations
of Renilla reporter plasmid pRL-CMV were also co-
introduced into cells as an internal control. Luciferase activ-
ities were measured and pGL3-Smac-P-Luc reporter activities
normalized to the pRL-CMV internal standard were presented
in the histogram with arbitrary units. As shown in Figure 2a
(panel 1), the Smac/Diablo promoter fragment P23 ( 600/
 100) harboring the BS2 and BS3 showed the strongest
response to E2F1. Removal of either binding site P2 or P3
drastically reduced the activity of promoter, indicating that
P23 ( 600/ 100) may be the minimal promoter of Smac in
response to E2F1 and maximal transactivation of Smac/
Diablo may require the combined use of BS2 and BS3. Simi-
larly, by adding the BS1 or BS4 on P23, the yielding P123
and P234 both exhibit signiﬁcantly reduced activity compared
with P23. To validate this conclusion in a more physio-
logical setting, we also compared the responsiveness of vari-
ous constructs to ER-E2F1 activation in H1299ER-E2F1 cells,
where ERE2F1 can be conditionally induced upon 4-OHT
Figure 2. Activation of Smac/Diablo promoter by E2F1. (a) Panel 1: determination of active E2F1-binding sites in Smac/Diablo promoter region. H1299 cells
were individually cotransfected with equal amount (100 ng) of eight luciferase reporter deletion constructs including pGL3-Smac-P1234, pGL3-Smac-P234,
pGL3-Smac-P34, pGL3-Smac-P0, pGL3-Smac-P123, pGL3-Smac-P23, pGL3-Smac-P3 and pGL3-Smac-P2 and either empty vector pEGFP-C1 (200 ng) or
E2F1 expressing vector pEGFP-E2F1 (200 ng). Renilla luciferase plasmid pRL-CMV was also introduced into cotransfected cells as internal control plasmid.
Cells were harvested 24 h after transfection and luciferase activities were assayed using the dual luciferase assay system. Fold activation values were measured
relativetothelevelsofRenillaluciferaseactivity.(a)Panel2:H1299ER-E2F1cellsweretransfectedwitheightluciferasereporterdeletionconstructsunderthesame
conditionsdescribedinpanel1of(a).Twentyhourslater,1mM4-OHTwasaddedtoincubateforanother24h.Resultsfromthedualluciferaseassaywereshownin
panel 2 of (a). (b) Panel 1: P23 is sufficient to activate Smac/Diablo promoter activity in response to E2F1. H1299 cells were cotransfected with luciferase reporter
plasmidspGL3-Smac-P23(100ng)orpGL3-Apaf-1( 396/+208)(100ng)andincombinationwithexpressionvectorspEGFP-C1(200ng)orpEGFP-E2F1(200ng).
Renilla luciferase plasmid pRL-CMV was also introduced into cotransfected cells as internal control. Fold activation values were measured relative to the levels
of Renilla activity. (b) Panel 2: H1299 ER-E2F1 cells were transfected with luciferase reporter plasmids pGL3-Smac-P23 (100 ng) and pGL3-Apaf-1( 396/+208)
(100ng)separately.Twentyhourspost-transfection,1mM4-OHTwasadded,andcellswereincubatedforanother24h.Resultsfromthedualluciferaseassaywere
showninpanel2of(b).(c)ActivationofSmac/DiablopromoterbyE2F1isdose-dependent.H1299cellswerecotransfectedwithpGL3-Smac-P23(200mg)andeither
pcDNA3vector(200mg),pcDNA3-E2F1(1-363)(200mg,anE2F1deletionmutant)orincreasingconcentrationsofpcDNA3-E2F1separately.Increasedamountof
plasmidpcDNA-E2F1from50,100and200mgisindicatedasthetrianglepointingup.Foreachcotransfection,RenillaluciferaseplasmidpRL-CMVwasintroduced
into the cells as internal control plasmid. Luciferase activity was measured and plotted. (d) Smac/Diablo promoter specifically responds to E2F1. H1299 cells were
cotranfected with reporter plasmid pGL3-Smac-P23 (200 mg) and equal concentration of activator plasmid pcDNA3, pcDNA3-E2F1, pcDNA3-E2F2 or
pcDNA3-E2F3. Luciferase activity was measured and plotted after normalizing with respect to Renilla luciferase activity. Renilla luciferase plasmid pRL-CMV
was introduced into each cotransfected cells as internal control plasmid. In (a–d), the western blottings indicating E2Fs expression levels are shown below their
respective histogram plots of luciferase assay. Luciferase and Renilla activity assayed using the Dual-Luciferase Reporter Assay System (Promega). Luciferase
values were corrected for transfection efficiency with Renilla activity. All experiments were independently performed in triplicate. Vertical error bars are the SDs
from the mean of the values within three SDs.
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ER-E2F1 stably transfected H1299 cells, and the result was
shown in Figure 2a (panel 2). These data imply that under
in vivo situations, BS1 and BS4 may individually exhibit
inhibitory effect on E2F1 activation, or alternatively, some
of the putative binding sites are not bona ﬁde E2F1-binding
site. P0, which does not contain any predicted E2F1-binding
sites, was included in this study in order for excluding the
possibility that the promoter region without E2F1 binding can
respond to it.
To conﬁrm whether Smac/Diablo promoter can be activated
by E2F1, We compared the responsiveness of the most active
promoter region P23 to that of the Apaf1 promoter Apaf1-
Luc( 396/+208) described elsewhere (23). As shown in
Figure 2b (panel 1), two promoters exhibit the similar pattern
and comparable fold increase under E2F1 activation. This
conclusion was further validated in H1299ER-E2F1 cells
and the result was shown in Figure 2b (panel 2). This result
further demonstrated that the Smac/Diablo was a bona ﬁde
E2F target gene. Next, H1299 cells were cotransfected with
pGL3-Smac-P23 and either pcDNA3 empty vector, pcDNA3-
E2F1(1-363) (an E2F1 transactivation domain-deﬁcient
variant) or increasing amounts of pcDNA3-E2F1 (from 50
to 200 ng). As shown in Figure 2c, increasing amount of
wild-type E2F1 resulted in correspondingly augmented
activation of Smac/Diablo P23, whereas the mutant E2F1 or
the empty vector failed to give rise to noticeable activation
of P23. To examine whether the responsiveness of Smac/
Diablo promoter is limited to E2F1, the other two E2F family
members E2F2 and E2F3 were tested along with E2F1 in the
same condition. As shown in Figure 2d, E2F2 and E2F3
exhibited much less activation than E2F1, suggesting that
Smac/Diablo promoter responds speciﬁcally and signiﬁcantly
to E2F1.
E2F1 binds to Smac/Diablo promoter in vivo
To determine if endogenous E2F1 protein directly interacts
with Smac/Diablo promoter, we performed the ChIP assay,
which allows the detection of the interaction between protein
and speciﬁc region of DNA in vivo. We designed four pairs of
oligonucleotide primers ﬂanking four putative E2F1-binding
sites as denoted in Figure 1a. HeLa cells were transfected
with or without pcDNA-HA-E2F1 prior to ChIP assay, and
as shown in Figure 3, in HeLa cells without transfection of
pcDNA-HA-E2F1, only BS3 fragment can be enriched by
antibody against E2F1 (the third panel, lane 4). However,
in HeLa cells ectopicly expressing E2F1, besides the more
enrichment of BS3, we also observed the relatively faint
band of BS2 (the second upper panel, lane 8), and the similar
enrichment was not detected after the ampliﬁcation of an
unrelated genomic DNA fragment b-actin (the lower panel,
lanes 4 and 8). It may imply that (i) endogenous E2F1 binds to
BS3 or weakly binds to BS2, and (ii) when E2F1 is upregu-
lated or overexpressed, it binds to both BS2 and BS3 to result
inamaximal activationofSmac/DIABLO.These resultsarein
good agreement with data obtained from the above-mentioned
reporter assay, in which P23 exhibits the highest activation of
Smac/Diablo promoter upon E2F1 binding. Taken together,
our results demonstrated the E2F1 interacts with Smac/Diablo
promoter, mainly through BS2 and BS3 regions.
E2F-1 induces Smac/DIABLO expression
To study the transcriptional regulation of Smac/DIABLO by
E2F1, we constructed a stable H1299 cell line, which consti-
tutively expresses an estrogen receptor-fused E2F1 protein
ER-E2F1 (48). In this cell line, E2F1 is fused to a modiﬁed
version of the estrogen receptor ligand-binding domain and
thusunabletobindestrogenyetretainshighafﬁnity for4-OHT
and full transactivation activity. In the absence of OHT, the
ER-E2F1 fusion protein is detained in the cytoplasm and
remains transcriptionally inactive. Upon the addition of
OHT, however, the fusion protein rapidly enters the nucleus
and induces transcription of E2F1 target genes. As shown in
Figure 4a, immunoﬂuorescence of the stable H1299 cell line
with anti-E2F1 antibody displayed an apparent nuclear
translocation of ER-E2F1 in the presence of 4-OHT, demon-
strating that the stable cell line we constructed was func-
tionally validated. To test if Smac/DIABLO expression is
regulated by E2F1, the stable H1299 cells were treated by
4-OHT for the indicated periods of time. Total RNA was
prepared and semi-quantitative RT–PCR was performed
using primer pair speciﬁc to gene Smac/Diablo. As shown
in Figure 4b, 6 h after addition of 4-OHT, similar to positive
control Cyclin A, which is known to be transcriptionally
upregulated by E2F1 (40), Smac/DIABLO mRNA tended to
increase and peaked at 8 h. As 4-OHT treatment time pro-
longed, the Smac/DIABLO mRNA level was kept relatively
steady. Western blotting was also performed for validating the
upregulation of Smac/DIABLO protein level. As shown in
Figure 4c, Smac/DIABLO exhibited an apparent increase
upon E2F1 activation. And Noxa, which is reported to be
upregulated by E2F1 (27), was used as a positive control
(Figure 4c, middle panel).
Figure 3. E2F1 binds to Smac/Diablo promoter in vivo. HeLa cells were
transfectedwithorwithoutpcDNA-HA-E2F1expressionvectorand24hlater,
celllysateswerepreparedandanalyzedbyChIPinthepresenceandabsenceof
E2F1 specific antibody (Santa Cruz). Products of ChIP and PCR amplification
wereanalyzedby2%agarosegelelectrophoresisandb-actinwasperformedas
a negative control. Primer pairs flanking indicated E2F1-binding sites used for
PCR were indicated in Figure 1a.
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Large numbers of reports have demonstrated that unrestrained
E2F1 could strongly induce apoptosis (13). To examine the
role of Smac/DIABLO in E2F1-induced apoptosis, we studied
the effect of reducing Smac/DIABLO expression on E2F1-
induced apoptosis. To achieve this, H1299 cell line stably
expressing ER-E2F1 was transfected with either Smac/
DIABLO speciﬁc siRNA, irrelevant control siRNA, or no
siRNA (Mock). Cells were collected for assessing the degree
of silencing of Smac/DIABLO expression by western analysis
using anti-Smac/DIABLO antibody, 48 h post-transfection.
As shown in Figure 5a,  70% of Smac/DIABLO expression
had been suppressed compared with controlled transfected
cells. To examine whether the suppression of Smac/DIABLO
affects E2F1-induced apoptosis, sample pairs were treated
with or without equal concentration of 4-OHT (1 mM) 48 h
Figure 5. Repression of Smac/DIABLO expression attenuates E2F1-induced
apoptosis. (a) H1299 cells stably expressing ERE2F1 were transfected with
either Smac/DIABLO specific siRNA (sc-36505; Santa Cruz), irrelevant
control siRNA (sc-37007; Santa Crutz) or Mock (water), and at 48 h post-
transfection, cells were harvested for western analysis and for further FACS
analysis to examine cell apoptosis. (b) H1299 cells stably expressing ERE2F1
were transfected with either Smac/DIABLO specific siRNA (sc-36505; Santa
Cruz), irrelevant control siRNA (sc-37007; Santa Cruz) or Mock (water), and
48 h later, cells were added with 1 mM 4-OHT for another 24 h incubation.
ThepercentagesofapoptosisofthecellswereexaminedbyFACSanalysisand
theresult(%Apoptosis)ispresentedinthebargraphrelativetotheapoptosisin
the mock-transfected cells, which is depicted as 100%. All the experiments
were independently performed in triplicate. Error bars indicate SD.
(a)
(b)
(c)
Figure 4. Activated E2F1 upregulates the expression of Smac/DIABLO.
(a) Subcellular localization of ERE2F1. H1299 cells stably expressing
ER-E2F1fusionproteinwereexaminedbyimmunofluorescencestainingusing
anE2F1specificpolyclonalantibody(H-137;SantaCruz)intheabsence(upper
panels) or in the presence (lower panels) of 1 mM 4-OHT. The nuclei were
stained with Hoechst 33342. (b) H1299 cells stably expressing ER-E2F1 were
incubatedinmediumcontaining0.1%serumfor48handthentreatedwith1mM
4-OHT for the indicated periods of time. Total RNA was prepared from
each treated samples and the equal amounts of RNA were employed in all
the RT–PCR experiments. Smac/Diablo mRNA level was compared on 2%
agarose gel. Cyclin A and b-actin mRNA levels were used as positive and
negative controls, respectively. (c) H1299 cells stably expressing ER-E2F1
were treated similarly as in (b), and treated cells were harvested and lysed
in RIPA buffer. An equal amount of total proteins from each time point in-
dicated was employed for western blotting. The Smac/DIABLO protein levels
were detected using a Smac-specific polyclonal antibody. Noxa and b-Actin
protein levels were served as positive and negative controls, respectively.
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jected for FACS analysis 24 h later. Comparing with the
mock and the irrelevant control, suppression of Smac/
DIABLO expression greatly attenuated the E2F1-induced
apoptosis (Figure 5b). These data suggested that Smac/
DIABLO is involved in the E2F1-induced apoptotic signaling
pathway, and blocking Smac/DIABLO expression signiﬁ-
cantly diminishes E2F1-inducedand Smac/DIABLO-involved
apoptosis.
DISCUSSION
Smac/DIABLO was ﬁrst identiﬁed as a proapoptotic factor
for its release from mitochondria to cytosol upon apoptotic
stimuli and initiating apoptosis by binding the IAP (Inhibitor
of Apoptosis Proteins), thereby relieving the inhibition on
caspases (29,30). Compartmentally stored in mitochondria
in the absence of apoptotic stimuli can be thought to be a
primary regulation of Smac/DIABLO protein level. Recent
studies have demonstrated that Smac/DIABLO is also subject
to polyubiquitination-mediated degradation through the inter-
action with IAPs (43), which could be thought as a secondary
control of the cellular level of Smac/DIABLO. The data
presented in this study suggest an additional control: Smac/
DIABLO is transcriptionally upregulated by E2F1 transcrip-
tion factor. However, the detailed mechanism underlying
the transcriptional or translational regulation by E2F1 on
Smac/DIABLO and how the balance of Smac/DIABLO is
maintained in the physiological circumstances still remain
to be elucidated.
E2F1 is best known for its role in regulating the timely
expression of genes required for DNA replication and cell
cycle progression (2). With growing number of novel target
genes involved in E2F1-induced apoptosis identiﬁed, it has
additionally been found that E2F1 exhibits functions in DNA
damageresponseandapoptosis.Apoptosis-relatedE2F1target
genes are involved in both extrinsic and intrinsic pathways and
are regulated by p53-dependent as well as p53-independent
mechanisms (4,13,44). This information emphasizes its role as
a key mediator of apoptosis and reminds us the complexities of
E2F1 in inducing apoptosis. Pu ¨tzer and coworker recently
reported a novel mitochondrial protein DIP (Death Inducing
Protein) as an E2F1 target gene (45) and not accidentally, the
other mitochondrial proteins, such as cytochrome c and AIF
(Apoptosis Inducing Protein) are also transcriptionally regu-
lated by E2F1 (46,47). Data from present study added still
more evidence for the assumption that E2F1 promotes
p53-independent apoptosis may through activating down-
stream mitochondrial factor. We have also analyzed the pro-
moter region of another proapoptotic mitochondrial protein
Omi/HtrA2, and interestingly enough, highly conserved
E2F1-binding sites were identiﬁed (W. Xie and M. Wu,
unpublished data). Although data has not yet accumulated
enough to conclude that the proapoptotic role of E2F1 for
p53-independent apoptosis is through modulating mitochon-
drial apoptotic factors, yet it opens up the possibility for
exploring the correlation between E2F1 and mitochondrial
proapoptotic factors.
Examination of the Smac/DIABLO promoter region
revealed four putative E2F1-binding sites with high homology
to the consensus E2F1-binding sequence 50-TTTSSCGC-30,
where S can be C or G. BS3 contains one C/T base substitution
in TTT, whereas BS2 has C/T and A/T two substitutions, this
may explain why BS3 exhibits stronger afﬁnity than BS2. We
noticed there is a base variation T/C in 30 CGC of BS1, which
could eliminate E2F1-binding afﬁnity to that site. In luciferase
and ChIP assays, BS2 and BS3 exhibit the evidential promoter
activation and E2F1-binding activity, as a result of that, the
responsiveness of Smac/Diablo promoter towards E2F1
appears to require the simultaneous binding to both sites.
This is because neither BS2 nor BS3 alone is shown to confer
sufﬁcient contribution to activating Smac/DIABLO expres-
sion. Data from luciferase assay imply that BS1 and BS4
may display inhibitory effects on transactivation of Smac/
DIABLO; however, we can not exclude the possibility that
the inhibitory effect may come from a different sequence(s)
near BS1 and BS4 and not from BS1 and BS4 per se. Data
from ChIP assay revealed that neither BS1 nor BS4-binding
site can be detected even in the presence of E2F1 overexpres-
sion. Based on these observations, we can conclude that BS1
and BS4 are unlikely to be the true E2F1-binding sites, despite
their extensive sequence homology to E2F1 consensus
binding sites. From ChIP assay, we demonstrated that BS3
has stronger afﬁnity to endogenous E2F1 than BS2, which
could be the underlying mechanism for differentially using
these two binding sites and making cell-fate decisions: to
enter cell cycle or to go for apoptosis. In healthy cells,
E2F1 is at a physiological level and only BS3 is activated,
thus theSmac/DIABLOiswell below the thresholdrequiredto
undergo apoptosis. Once E2F1 is unrestrainedly expressed
(overexpression), both BS2 and BS3 are employed, resulting
in an enhanced production of Smac/DIABLO. The detailed
mechanism for cells to make a choice between life and death
still await further investigation. Nonetheless, we propose a
hypothetical model to illustrate the possible mechanism by
which E2F1 activates Smac/DIABLO expression by dif-
ferential binding to E2F1 responsive elements located at
Smac/Diablo upstream regulatory region, and the detailed
descriptions are outlined in Figure 6.
It is interesting to note that when the newly-released version
of MatInspector (professional version 7.4) was used to analyze
the Smac/Diablo promoter, a few uncharacterized putative
E2F1-binding sites were disclosed, Most of which are located
between BS2 and BS3 (data not shown), which may partially
explain why the promoter region P23 containing BS2 and BS3
displays the highest activation by E2F1.
In summary, our data show that E2F1 can bind to the
Smac/Diablo promoter, and thereby activate its expression
at mRNA and proteinlevels.Using the H1299/ER-E2F1stable
cell line where E2F1 activity can be conditionally induced, we
demonstrated that upon 4-OHT treatment, upregulated E2F1
results in an enhanced mitochondria-mediated apoptosis with
an increased expression of Smac/DIABLO. Consistently,
diminution of Smac/DIABLO expression by RNAi signiﬁ-
cantly attenuates apoptosis induced by E2F1. Our present
data may add further evidence to a growing list of mito-
chondrial factors which are under E2F1 regulation. To gain
a further understanding of the molecular mechanism by which
E2F1 promotes p53-independent apoptosis could shed light
on the gene therapy for tumors, of which majority are p53
defective.
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